Welcome to our dedicated page for Perrigo Co Plc SEC filings (Ticker: PRGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Perrigo Company plc (NYSE: PRGO) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other key documents filed with the Securities and Exchange Commission. Perrigo is incorporated in Ireland and files its reports as a foreign private issuer with ordinary shares listed on the New York Stock Exchange under the symbol PRGO.
Through its Form 8-K filings, Perrigo reports material events such as quarterly earnings releases, strategic reviews and significant transactions. Recent 8-Ks have furnished earnings results for its Consumer Self-Care Americas and Consumer Self-Care International segments, described non-GAAP measures such as adjusted operating income, adjusted diluted earnings per share, organic net sales and constant currency net sales, and outlined the items excluded in these non-GAAP metrics, including amortization of acquired intangibles, restructuring charges, unusual litigation, impairment charges, divestiture gains or losses and infant formula remediation.
Other 8-K filings detail corporate actions such as the entry into a Master Sale and Purchase Agreement to sell Perrigo’s Dermacosmetics branded business in Northern Europe, the Netherlands and Poland, and executive leadership changes and related compensation arrangements. These filings provide insight into how the company is managing its portfolio, capital allocation and organizational structure.
On Stock Titan, users can view Perrigo’s filings as they are made available from EDGAR and use AI-powered summaries to understand the main points of lengthy documents. This includes context around earnings-related disclosures, explanations of non-GAAP reconciliations and highlights from transaction agreements and governance updates. For investors tracking PRGO, this page serves as a centralized view of Perrigo’s regulatory reporting history and ongoing disclosure practices.
Perrigo Company plc executive Robert Willis reported routine equity compensation activity. He exercised 2,070 Restricted Stock Units into an equal number of ordinary shares at a reported price of $10.85 per share. To cover tax obligations, 1,081 ordinary shares were withheld, leaving him with 48,924 shares held directly after the transactions.
Perrigo Company plc CEO Patrick Lockwood-Taylor reported routine equity compensation activity. He exercised Restricted Stock Units into 17,834 ordinary shares on April 2, 2026, at a reported share value of $10.85. To cover tax obligations, 9,123 shares were withheld and disposed of by the issuer. After these transactions, he directly owns 110,846 ordinary shares. Each Restricted Stock Unit represented the right to receive one ordinary share.
Perrigo Company plc EVP & Chief Financial Officer Eduardo Guarita Bezerra exercised 6,369 Restricted Stock Units into the same number of ordinary shares on April 2, 2026 at a stated price of $10.85 per share. A separate transaction shows 1,551 ordinary shares were disposed of as a tax-withholding transaction, rather than an open-market sale. Following these transactions, Bezerra directly owns 77,760 ordinary shares. Each Restricted Stock Unit represented a contingent right to receive one ordinary share, with units vesting in three equal annual installments beginning April 5, 2025.
Perrigo Co PLC amendment: The Vanguard Group filed an amended Schedule 13G reporting 0 shares beneficially owned of Perrigo Co PLC common stock, representing 0% of the class.
The filing explains an internal realignment at The Vanguard Group effective January 12, 2026, under which certain subsidiaries will report ownership separately and Vanguard no longer is deemed to beneficially own securities held by those subsidiaries.
Perrigo Company plc entered into an amended and restated senior secured credit agreement with JPMorgan and other lenders. The facility includes a $1.0 billion revolving credit facility maturing March 20, 2031 and a $972.4 million term loan B maturing April 20, 2029, with the term loan’s balance and maturity unchanged.
Perrigo drew on the revolver to fully prepay its prior Term A loans, including accrued interest, fees and transaction costs. The agreement removes the credit spread adjustment on revolver loans, adds secured net leverage and cash interest coverage covenants, and continues to secure obligations with substantially all tangible and intangible assets of key subsidiaries.
Perrigo Company plc is asking shareholders to vote at its April 30, 2026 AGM in Dublin on nine director nominees, auditor ratification, say‑on‑pay, a new 2026 Long‑Term Incentive Plan, and renewed Irish share issuance and pre‑emption opt‑out authorities.
The proxy highlights 2025 progress under Perrigo’s “3‑S” plan, including reported net sales of $4.3 billion, adjusted operating income of $622 million with a 14.6% margin, and adjusted EPS of $2.75, up 7%. Cost programs delivered roughly $163 million and $157 million in gross annualized savings, while an agreed Dermacosmetics divestiture is valued at up to €327 million.
Executive pay remains heavily performance‑based, with about 87% of the CEO’s target compensation at risk and 2025 annual incentive payouts below target. The board emphasizes strong governance, majority‑independent membership, proxy access, ESG and cybersecurity oversight, and strict anti‑hedging and share ownership policies.
Parker Geoffrey M. reported acquisition or exercise transactions in this Form 4 filing.
Perrigo Company director Geoffrey M. Parker received a grant of 3,024 Restricted Stock Units (RSUs) on March 13, 2026. Each RSU represents a contingent right to receive one Perrigo ordinary share, with this grant scheduled to vest on March 13, 2027.
The filing shows this as a compensation-related award, not an open-market purchase or sale. Following the grant, Parker holds 3,024 RSUs, 28,912 ordinary shares directly, 25,879 ordinary shares through a revocable trust where he and Jill Parker are trustees, and 17,375 ordinary shares through a Roth IRA.
Alford Bradley A reported acquisition or exercise transactions in this Form 4 filing.
Perrigo Company plc director Bradley A. Alford received a grant of 3,024 Restricted Stock Units on ordinary shares as equity compensation. Each unit represents a contingent right to receive one ordinary share, with the award scheduled to vest on March 13, 2027.
Following this grant, Alford holds 3,024 Restricted Stock Units and 41,160.148 ordinary shares directly. This is a compensation-related award, not an open-market purchase or sale, and reflects additional alignment with Perrigo’s equity over time as the units vest.
Perrigo Company plc executive Robert Willis, EVP & CHRO, reported compensation-related equity activity involving restricted stock units and ordinary shares. On March 6, 2026, he exercised performance-based and time-based restricted stock units into a total of 4,501 ordinary shares, with related non-derivative entries showing a reported price of $10.72 per share. The filing also shows a separate grant of 8,019 ordinary shares as a share award. To cover tax obligations, 6,524 ordinary shares were withheld through transactions coded “F,” which are not open-market sales. Following these transactions, Willis directly holds 47,935 Perrigo ordinary shares.